Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 6/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134569 | 0.88 | CNR2 (0.41) | CNR2KDM2BHRH3LMNA | |
| SCHEMBL4934309 | 0.85 | KDM2B (0.40) | CNR2KDM2BHRH3SCD | |
| SCHEMBL4141295 | 0.84 | NPC1 (0.40) | CNR2HRH3LMNA | |
| SCHEMBL4284865 | 0.81 | CNR2 (0.42) | CNR2HRH3 | |
| SCHEMBL4130923 | 0.81 | LMNA (0.44) | HRH3LMNASCD | |
| SCHEMBL4927858 | 0.80 | TP53 (0.39) | CNR2KDM2BHRH3LMNASCD | |
| SCHEMBL4137164 | 0.79 | HRH3 (0.44) | CNR2HRH3KCNH2SCD | |
| SCHEMBL4929438 | 0.78 | CNR2 (0.41) | CNR2HRH3SCD | |
| SCHEMBL4141279 | 0.78 | SCD (0.40) | HRH3LMNASCD | |
| SCHEMBL4130513 | 0.78 | SCD (0.39) | CNR2HRH3KCNH2SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | HRH3, HRH4, HRH1 | CNR2 75/4885KDM2B 577/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.